The significance of serum anti- rituximab (anti-CD20 monoclonal antibody) antibodies in treatment response of patients with B- cells malignancy
DOI:
https://doi.org/10.36320/ajb/v11.i2.8159Keywords:
Immunotherapy, Rituximab, B- cell malignancy, Chimeric antibodiesAbstract
Background: The chimeric anti-CD20 monoclonal antibody, rituximab, is an effective therapeutic agent used for treating patients with B- cell disorders, however there is a significant variation in therapy response among patients and relapse is common. Furthermore, it is unclear why a class of patients is initially not responding and other responding become refractory and later resistant to further treatment.
Aim: To study the significance of serum anti- rituximab antibodies in the patients initially responding to the treatment and became refractory and resistant to the treatment.
Downloads
References
Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood., (1997). 90:2188–95. [PubMed: 9310469]
Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol.,(1999). 17:1851–7. [PubMed: 10561225]
Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am.,(2012). 26:447–81. [PubMed: 22520975]
Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun.,(2005). 8:140–74. [PubMed: 15564720]
Benjamin Bonavida. Postulated Mechanisms of Resistance of B-NHL to Rituximab Treatment Regimens: Strategies to Overcome Resistance. Semin Oncol.,(2014). 41(5): 667–677. doi:10.1053/j.seminoncol.2014.08.006.
Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia.,(2008). 22:179–85. [PubMed: 17898787]
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood.,(2002). 99:754–8. [PubMed: 11806974]
Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol., (2003). 21:3940–7. [PubMed: 12975461]
Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res.,(2007). 67:10556–63. [PubMed: 17975000]
Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol.,(2002). 119:412–6. [PubMed: 12406079]
Jazirehi AR, Vega MI, Bonavida B. Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy. Cancer Res.,(2007). 67:1270–81. [PubMed: 17283164]
Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res.,(2009). 15:2523–30. [PubMed: 19276251]
Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol.,(2006). 176:2600–9. [PubMed: 16456022]
Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood.,(2009). 114:2560–1. [PubMed: 19762501]
Arnold JN, Radcliffe CM,Wormald MR et al. The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin.J Immunol.,(2004). 173:6831–40.
Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol.,(1992).52:125–262. doi: 10.1016/S0065-2776(08)60876-7. [PubMed] [CrossRef] [Google Scholar]
McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol.,(1998).16:2825–2833.
doi: 10.1200/JCO.1998.16.8.2825. [PubMed] [CrossRef] [Google Scholar]
Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol.,(2014).41:667–677. doi: 10.1053/j.seminoncol.2014.08.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Mabthera 100 mg concentrate for solution for infusion [summary of product characteristics]. Roche Products, Welwyn Garden City., (2017). https://www.medicines.org.uk/emc/medicine/2570. Accessed 18 Sept 2017.
Rituxan® (rituximab) injection, for intravenous use. Genentech, South San Francisco. (2016). https://www.gene.com/download/pdf/rituxan_prescribing.pdf. Accessed 21 Jun(2017).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Aleen Sardar Al-Noori, Zaki Ali Mohammed, Ahmed Mohammed Salih, Soleen Sardar Zuhdi, Hishyar A. Njeeb
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
